Berberine (BBR) exerts an effective protection for diabetic retinopathy (DR), but the underlying key molecular mechanism remains unknown; this study investigated the protective mechanism of BBR on DR by alleviating cell pyroptosis. A rat DR model was established and treated with BBR, and histological analyses, including hematoxylin and eosin staining, Nissl staining, and immunofluorescence, were executed to evaluate tissue changes. Core target genes were identified using the GeneCards database, Venn diagram analysis, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, protein-protein interaction networks, and molecular docking. Validation of key genes was performed via reverse transcription-quantitative polymerase chain reaction (RT-qPCR), Western blot, and RNA interference. BBR improved retinal morphology, reduced edema, and restored the arrangement of retinal ganglion cells in DR rats. BBR significantly reduced the levels of pyroptosis markers such as IL-1β and IL-18, which were elevated in DR. Network pharmacology identified 10 hub genes, with six genes (JUN, STAT3, AKT1, TP53, IL-1B, EGFR) further analyzed. BBR reversed DR-induced upregulation of JUN, STAT3, and AKT1 at both the mRNA and protein levels, as confirmed by RT-qPCR and Western blot. Silencing these genes enhanced cell viability and amplified BBR's protective effects. Altogether, BBR alleviates retinal inflammation and pyroptosis in diabetic retinal ganglion cells by targeting JUN, STAT3, and AKT1, providing insights into its therapeutic potential for DR.
| [1] |
Zhai J, Li Z, Zhang H, et al. Berberine protects against diabetic retinopathy by inhibiting cell apoptosis via deactivation of the NF-κB signaling pathway. Mol Med Rep. 2020; 22(5): 4227-4235.
|
| [2] |
Moreno A, Lozano M, Salinas P. Diabetic retinopathy. Nutr Hosp. 2013; 28 Suppl 2(suppl 2): 53-56.
|
| [3] |
Yang Y, Tong H, Ye Z-F, Xu Z-C, Tao T. Research progress of neurovascular units involved in ischemic stroke. Ibrain. 2025; 11(4): 492-503.
|
| [4] |
Jingi AM, Tankeu AT, Ateba NA, Noubiap JJ. Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis. BMC Endocr Disord. 2017; 17(1): 63.
|
| [5] |
Yuan J, Zhang L, Jia P, Xin Z, Yang JK. Early onset age increased the risk of diabetic retinopathy in type 2 diabetes patients with duration of 10–20 years and HbA1C ≥7%: a hospital-based case-control study. Int J Endocrinol. 2021; 2021: 5539654.
|
| [6] |
Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. Br J Ophthalmol. 2017; 101(10): 1346-1351.
|
| [7] |
Vande Walle L, Lamkanfi M. Pyroptosis. Curr Biol. 2016; 26(13): R568-R572.
|
| [8] |
Huang L, You J, Yao Y, Xie M. High glucose induces pyroptosis of retinal microglia through NLPR3 inflammasome signaling. Arq Bras Oftalmol. 2021; 84(1): 67-73.
|
| [9] |
Chen W, Zhao M, Zhao S, et al. Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline. Inflamm Res. 2017; 66(2): 157-166.
|
| [10] |
Yang L, Li Z, Fang J. Scutellarin alleviates diabetic retinopathy via the suppression of nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing protein 3 inflammasome activation. Curr Eye Res. 2024; 49(2): 180-187.
|
| [11] |
Laurindo LF, Santos ARO, Carvalho ACA, et al. Phytochemicals and regulation of NF-kB in inflammatory bowel diseases: an overview of in vitro and in vivo effects. Metabolites. 2023; 13(1): 96.
|
| [12] |
Chen Y, Li Q, Zhao S, et al. Berberine protects mice against type 2 diabetes by promoting PPARγ-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis. Biochem Pharmacol. 2023; 218: 115928.
|
| [13] |
Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020; 11(1): 5015.
|
| [14] |
Lv X, Zhao Y, Yang X, et al. Berberine potentiates insulin secretion and prevents β-cell dysfunction through the miR-204/SIRT1 signaling pathway. Front Pharmacol. 2021; 12: 720866.
|
| [15] |
Li N, Chen JL, Sun YJ, et al. Berberine attenuates the expression of NLRP3 and downstream inflammasome effectors in diabetic retinopathy. J Nat Med. 2025; 79(5): 1091-1105.
|
| [16] |
Yang WL, Zhang CY, Ji WY, et al. Berberine metabolites stimulate GLP-1 secretion by alleviating oxidative stress and mitochondrial dysfunction. Am J Chin Med. 2024; 52(1): 253-274.
|
| [17] |
Zhang R, Zhu X, Bai H, Ning K. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019; 10: 123.
|
| [18] |
Turhan B, Sağlam S, Yücel MO, et al. Comparison of topical hypericum perforatum and metformin effectiveness in wound healing in streptozotocin-induced diabetic rats. Front Endocrinol. 2025; 16: 1691294.
|
| [19] |
Li Y, Liu Y, Li Y, et al. Integrated lipidomics and network pharmacology analysis to determine how Gu Fu Sheng Capsule improves lipid metabolism in rats with steroid-induced osteonecrosis of the femoral head. J Tradit Complement Med. 2025; 15(7): 687-701.
|
| [20] |
Himasa FI, Singhal M, Ojha A, Kumar B. Prospective for diagnosis and treatment of diabetic retinopathy. Curr Pharm Des. 2022; 28(7): 560-569.
|
| [21] |
Li N, Guo XL, Xu M, et al. Network pharmacology mechanism of Scutellarin to inhibit RGC pyroptosis in diabetic retinopathy. Sci Rep. 2023; 13(1): 6504.
|
| [22] |
Jiang Y, Huang K, Lin X, et al. Berberine attenuates NLRP3 inflammasome activation in macrophages to reduce the secretion of interleukin-1β. Ann Clin Lab Sci. 2017; 47(6): 720-728.
|
| [23] |
Miyazawa T, Nakagawa K, Shimasaki S, Nagai R. Lipid glycation and protein glycation in diabetes and atherosclerosis. Amino Acids. 2012; 42(4): 1163-1170.
|
| [24] |
Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020; 21(5): 1835.
|
| [25] |
Liu H, Stepicheva NA, Ghosh S, et al. Reducing Akt2 in retinal pigment epithelial cells causes a compensatory increase in Akt1 and attenuates diabetic retinopathy. Nat Commun. 2022; 13(1): 6045.
|
| [26] |
Xia Z, Yang X, Zheng Y, Yi G, Wu S. Plasma levels and diagnostic significance of miR-335-3p and EGFR in diabetic retinopathy. Clin Lab. 2022; 68(4).
|
| [27] |
Sugimoto M, Cutler A, Shen B, et al. Inhibition of EGF signaling protects the diabetic retina from insulin-induced vascular leakage. Am J Pathol. 2013; 183(3): 987-995.
|
| [28] |
Yang J, Shen Y. Ginkgo Biloba extract attenuates diabetic retinopathy progression by modulating TP53 ubiquitination in a rat model. Mol Biol Rep. 2025; 53(1): 10.
|
| [29] |
Yu C, Qiu Y, Yan D, Zhou W, Wan J, Yu J. Berberine treatment inhibits ferroptosis in NIT-1 murine pancreatic cell line via inhibiting OGT expression levels. Sci Rep. 2025; 15(1): 18504.
|
| [30] |
Kong Y, Yang H, Nie R, Zhang X, Zhang H, Nian X. Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence. Eur J Med Res. 2025; 30(1): 477.
|
Rights & permissions
2026 The Author(s). Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH.
PDF
(11155KB)
